- Dova Pharmaceuticals (NASDAQ:DOVA) initiated with Outperform rating and $44 (79% upside) price target at Raymond James. Shares up 6% premarket.
- Deciphera Pharmaceuticals (NASDAQ:DCPH) initiated with Outperform rating and $47 (33% upside) price target at Raymond James.
- Assertio Therapeutics (NASDAQ:ASRT) downgraded to Neutral at Janney. Shares down 15% premarket after settling Oxycontin patent dispute with Purdue Pharma.